NCT02795065View on ClinicalTrials.gov

Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Venous Thromboembolism
Interventions
DRUG

Enoxaparin

Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism

DRUG

Bemiparin

Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism

All Listed Sponsors
lead

Mohamed Sayed Mohamed Abbas

OTHER

NCT02795065 - Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients | Biotech Hunter | Biotech Hunter